The Appraisal Committee was due to meet on 16 February 2016 to discuss the use of lenalidomide for treating relapsed or refractory mantle cell lymphoma. The company has indicated that they will not be making a submission for this appraisal. Consequently, NICE will suspend the appraisal whilst we consider the next steps.